The reasons for MyCyFAPP

Patients with CF suffer from lifelong pancreatic insufficiency, what implies the lack of digestive enzymes secretion to the small intestine and thus the impossibility of nutrients digestion. For that reason, patients have to follow the Pancreatic Enzyme Replacement Therapy (PERT), which is the exogenous intake of digestive enzymes. However, the optimal dosage is a challenge to determine, since it depends on the characteristics of each meal and on the individual conditions of each patient. The raison d'etre of this project is the need to develop/create an evidence-based tool to tackle the existing gap on the adapted-to-patients enzyme replacement dosage therapy.

logo DEFINITIVO copy

euflagProject funded by the European Union
under the Grant Agreement number 643806


MyCyFAPP is a project funded by the European Commission under the Research and Innovation Framework Programme “Horizon 2020”